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STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN 
EMERGING TARGET IN THROMBOSIS RESEARCH. 
 
Charlotte Bouckaert, Christelle Vancraeynest, Eduard Dolušić, Raphaël Frédérick, Lionel Pochet 
Namur Medecine & Drug Innovation Center (NAMEDIC-NARILIS), University of Namur, rue de 
Bruxelles 61, 5000 Namur, Belgium 
 
Thrombotic diseases, in which a deregulated haemostatic activity occurs, remain a major 
concern in medicine. Anticoagulants are part of the strategies to address these disorders. 
However current available drugs are still associated with risk of severe bleeding 
complications and thus, novel antithrombotics are required1. 
 
In this perspective, coagulation factor XIIa (FXIIa), a serine protease implicated in the 
coagulation cascade, recently emerged as a promising target in the development of such 
agents2. Indeed, it was demonstrated that FXII deficiency or inhibition protects against 
thrombosis without causing spontaneous bleeding in mice3. 
 
Based on these considerations, the aim of our project is to develop novel selective FXIIa 
inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds 
could also be a good starting point for the development of new antithrombotic drugs.  
 
The 3-carboxamide coumarins (figure 1) are to date the only nonpetidic and selective 
inhibitors of FXIIa described in literature4. However, their low solubility and poor 
pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis. As 
consequence, we need to improve these characteristics while keeping the selectivity and 
potency towards FXIIa. 
 
 
 
In this work, we first synthesized new coumarins with improved solubility. Their inhibition 
potency was then measured on FXIIa and finally, their stability was evaluated.  
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Figure 1 : 3-carboxamide coumarin scaffold 
